Serum lactate dehydrogenase level is a prognostic factor in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy

被引:47
|
作者
Turen, Selahattin
Ozyar, Enis [1 ]
Altundag, Kadri
Gullu, Ibrahim
Atahan, Ibtisam L.
机构
[1] Hacettepe Univ, Fac Med, Dept Radiat Oncol, TR-06100 Ankara, Turkey
[2] Hacettepe Univ, Fac Med, Dept Internal Med, TR-06100 Ankara, Turkey
[3] Hacettepe Univ, Fac Med, Dept Med Oncol, TR-06100 Ankara, Turkey
关键词
nasopharyngeal carcinoma; chemotherapy; radiotherapy; prognostic factors; LDH;
D O I
10.1080/07357900701209103
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We investigated the treatment results and probable prognostic factors in patients with locoregionally advanced nasopharyngeal carcinoma (NPC) treated with neoadjuvant chemotherapy (NCT) plus conventional radiotherapy (RT) or concomitant chemoradiotherapy (CCRT) at our hospital. We retrospectively evaluated 61 patients (48 males, 13 females) with locoregionally advanced NPC treated either with 2 cycles of NCT plus RT (Group A, 37 patients) or with three cycles of NCT plus CCRT (Group B, 24 patients) between September 1995 and October 2002. According to the AJCC 1997 classification system, 19 patients had Stage III disease and 42 had Stage IV. NCT consisted of cisplatin and 5-fluorouracil. Total RT doses were ranged between 59.4-71.6 Gy (median: 66.2 Gy). Concomitant cisplatin (75 mg/ m(2)) was given on first days of Weeks 1, 4, 7 of CCRT. Patient sex, histopathologic subtype, T status, ECOG performance status, stage, serum lactate dehydrogenase (LDH) level, and cranial nerve involvement at diagnosis were comparable in the 2 groups. There were statistically significant differences between median follow-up times and N status for the 2 groups. Fifty-five (90.2 percent) patients completed all planned NCT. Univariate analysis revealed the pretreatment LDH level as the only statistically significant prognostic factor for disease-free survival (DFS) and overall survival (OS). Four-year DFS rates were 55.9 percent and 21.3 percent for patients with normal and high serum LDH levels, respectively (P = 0.04). Four-year OS rates were 68.7 percent and 28.5 percent for patients with normal and high serum LDH levels, respectively (P = 0.01). Multivariate analysis also revealed that high serum LDH level was the only independent risk factor that predicted OS. The relative risk was 2.43 (95% CI: 1.08-5.45) for patients with high serum LDH levels (P = 0.03). No independent risk factors associated with DFS were found for other prognosticators. Our study demonstrated that high serum LDH level is the only independent unfavorable risk factor for OS in patients with locoregionally advanced NPC who were treated with NCT plus RT or CCRT.
引用
收藏
页码:315 / 321
页数:7
相关论文
共 50 条
  • [1] Serum LDH level is a prognostic factor in locoregionally advanced nasopharyngeal carcinoma (NPC) patients treated with chemoradiotherapy
    Turen, S
    Ozyar, E
    Altundag, K
    Gullu, I
    Atahan, IL
    [J]. RADIOTHERAPY AND ONCOLOGY, 2004, 73 : S306 - S306
  • [2] Serum LDH level is a prognostic factor in locoregionally advanced nasopharyngeal carcinoma (NPC) patients treated with chemoradiotherapy
    Turen, S
    Ozyar, E
    Altundag, MK
    Gullu, I
    [J]. LUNG CANCER, 2004, 46 : S82 - S82
  • [3] Serum lactate dehydrogenase level in patients with nasopharyngeal carcinoma
    Liaw, CC
    Wang, CH
    Huang, JS
    Kiu, MC
    Chen, JS
    Chang, HK
    [J]. ACTA ONCOLOGICA, 1997, 36 (02) : 159 - 164
  • [4] Pretreatment body mass index as an independent prognostic factor in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy: Findings from a randomised trial
    Huang, Pei-Yu
    Wang, Cheng-Tao
    Cao, Ka-Jia
    Guo, Xiang
    Guo, Ling
    Mo, Hao-Yuan
    Wen, Bi-Xiu
    Wu, Yi-Shan
    Mai, Hai-Qiang
    Hong, Ming-Huang
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 (08) : 1923 - 1931
  • [5] Serum lactate dehydrogenase (LDH) level as a prognostic factor for the patients with advanced gastric cancer
    Lee, H.
    Yuh, Y.
    Kim, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] Serum C-reactive protein predicts poor prognosis in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy
    Zeng, Y. C.
    Wu, R.
    Xiao, Y. P.
    Chi, F.
    Xue, M.
    Zhang, Z. Y.
    Xing, R.
    Zhong, W. Z.
    Wang, S. L.
    Tian, X.
    Chen, W.
    Chen, J. J.
    Wu, L. N.
    [J]. CURRENT ONCOLOGY, 2015, 22 (01) : 20 - 24
  • [7] Prognostic value of pretreatment serum lactate dehydrogenase level in nasopharyngeal carcinoma in early stage
    Wei, Zhengbo
    [J]. CANCER SCIENCE, 2018, 109 : 527 - 527
  • [8] Prognostic Nomogram For Locoregionally Advanced Nasopharyngeal Carcinoma
    Jiang, Yanming
    Qu, Song
    Pan, Xinbin
    Huang, Shiting
    Zhu, Xiaodong
    [J]. SCIENTIFIC REPORTS, 2020, 10 (01)
  • [9] Prognostic Nomogram For Locoregionally Advanced Nasopharyngeal Carcinoma
    Yanming Jiang
    Song Qu
    Xinbin Pan
    Shiting Huang
    Xiaodong Zhu
    [J]. Scientific Reports, 10
  • [10] Prognostic implications of post-therapy 18F-FDG PET in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy
    Chan, Sheng-Chieh
    Kuo, Wen-Han
    Wang, Hung-Ming
    Chang, Joseph Tung-Chieh
    Lin, Chien-Yu
    Ng, Shu-Hang
    Hsu, Cheng-Lung
    Chang, Kai-Ping
    Liao, Chun-Ta
    Lin, Yu-Jr
    Yen, Tzu-Chen
    [J]. ANNALS OF NUCLEAR MEDICINE, 2013, 27 (08) : 710 - 719